[1] Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther. 2015. 42(8): 977-89.
[2] Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008. 103(12): 3167-82.
[3] Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012. 142(1): 46-54.e42; quiz e30.
[4] Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013. 145(1): 158-165.e2.
[5] Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012. 380(9853): 1590-605.
[6] Zhou Y, Chen H, He H, et al. Increased Enterococcus faecalis infection is associated with clinically active Crohn disease. Medicine (Baltimore). 2016. 95(39): e5019.
[7] Adami HO, Bretthauer M, Emilsson L, et al. The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut. 2016. 65(6): 889-93.
[8] Grivennikov SI, Cominelli F. Colitis-Associated and Sporadic Colon Cancers: Different Diseases, Different Mutations. Gastroenterology. 2016. 150(4): 808-10.
[9] Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014. 146(2): 383-91.
[10] Adachi M, Kurotani R, Morimura K, et al. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut. 2006. 55(8): 1104-13.
[11] Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006. 55(9): 1341-9.
[12] Zhao X, Fan J, Zhi F, et al. Mobilization of epithelial mesenchymal transition genes distinguishes active from inactive lesional tissue in patients with ulcerative colitis. Hum Mol Genet. 2015. 24(16): 4615-24.
[13] Noble CL, Abbas AR, Lees CW, et al. Characterization of intestinal gene expression profiles in Crohn's disease by genome-wide microarray analysis. Inflamm Bowel Dis. 2010. 16(10): 1717-28.
[14] Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007. 13(7): 807-21.
[15] Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010. 16(1): 112-24.
[16] Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT. J Cell Biochem. 2007. 101(4): 830-9.
[17] Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980. 1(8167): 514.
[18] Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003. 112(12): 1776-84.
[19] Kim B, Cheon JH, Moon HJ, et al. Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study. J Gastroenterol Hepatol. 2016. 31(1): 126-32.
[20] Egan JM. Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist. N Engl J Med. 2015. 373(20): 1973-5.
[21] Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005. 5(9): 744-9.
[22] Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 2010. 10(5): 365-76.
[23] Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009. 139(5): 871-90.
[24] Zou J, Luo H, Zeng Q, Dong Z, Wu D, Liu L. Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med. 2011. 9: 97.
[25] Gu Y, Wang Q, Guo K, et al. TUSC3 promotes colorectal cancer progression and epithelial-mesenchymal transition (EMT) through WNT/β-catenin and MAPK signalling. J Pathol. 2016. 239(1): 60-71.
[26] Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet. 2008. 9(1): 9-14.
[27] Vuoriluoto K, Haugen H, Kiviluoto S, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011. 30(12): 1436-48.
[28] Reddy AT, Lakshmi SP, Reddy RC. PPARγ as a Novel Therapeutic Target in Lung Cancer. PPAR Res. 2016. 2016: 8972570.